Otsuka Pharmaceutical Companies (U.S.)

Our commitment to patients and their families extends beyond developing treatments; it encompasses emotional, psychological, and practical support to navigate the demanding journey of autosomal dominant polycystic kidney disease (ADPKD) patients. Our patient promise is at the core of everything we do. Read more from Lina Floren Smith, Vice President of Nephrology and Immunology business in the article below.

Today, we are pleased to present, in collaboration with Lundbeck LLC, the 'I Wish I Knew' national public education campaign, featuring Barbara Corcoran, aimed at helping the over 11 million family caregivers of people with Alzheimer's learn more about the symptoms of agitation in Alzheimer's dementia.  Renowned entrepreneur, author, investor and caregiving advocate, Barbara Corcoran bravely shares her family's difficult journey with her mother's Alzheimer's dementia, in hopes that others will benefit from what she wishes she knew when her mother was diagnosed. "These changes felt heartbreaking for my siblings and me to watch, because our mother had never been this way. She was a lovebug. We didn't recognize the agitated person she had become" said Barbara, who lost her mother in 2012. Read more about Barbara's story and the 'I Wish I Knew' campaign: https://lnkd.in/gtHp3aVP

We are thrilled to attend the American Society of Nephrology's Kidney Week 2024 in San Diego and look forward to meeting kidney professionals from around the world. For those registered to attend, we invite you to visit us at Booth #929 and learn more about the autoimmune kidney disease Immunoglobulin A nephropathy (IgA Nephropathy). Our perseverance and long-term commitment in the nephrology space has led to major breakthroughs, giving patients renewed hope and clinicians more options than ever before. Discover our commitment: https://lnkd.in/g3TsScPa #DefyLimitation #KidneyWeek2024 #KidneyWk

We are proud to announce that Jnana Therapeutics is now part of Otsuka Pharmaceutical Co., Ltd. Jnana will continue to be based in Boston and operate as a direct subsidiary of Otsuka America, Inc. We look forward to continuing our mission to develop small molecules against challenging-to-drug targets for under-addressed diseases and advancing JNT-517 into a pivotal Phase 3 study for PKU in early 2025. Read more: https://bit.ly/3ZD6b2q #acquisition #pharmaceuticals #biotechnology

Great Place To Work US and Fortune magazine have selected Otsuka for the 2024 Fortune Best Workplaces in BioPharma™ List, ranking at #6.      This recognition would not be possible without Otsuka-people and their shared commitment to our mission of creating new products for better health worldwide.      We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care for the communities we serve.      Learn more about the list here: https://bit.ly/3XDXH9Z

Research has found that nearly half of caregivers in the U.S. who provide care for an older adult do so for someone living with Alzheimer's disease or dementia.  As a healthcare company, Otsuka is continuously gaining a deeper understanding of how the lives of family caregivers are impacted so that we can offer meaningful resources that provide support and alleviate some of the challenges experienced along their unique journeys.    Together, we have the potential to improve the future for caregivers if we all do our part.    Discover our caregiver commitment: https://bit.ly/4dhcLix

We firmly stand with the World Health Organization in their mission to enhance patient safety globally for World Patient Safety Day.     Patient safety and care is at the core of our purpose.   From spearheading pioneering research to designing innovative products and healthcare solutions, our commitment to improving health outcomes remains unwavering for the communities we serve.     Let’s continue to prioritize patient safety together for a healthier future.     Learn more about World Patient Safety Day and the critical importance of patient safety: https://bit.ly/3VGfdrW      #WorldPatientSafetyDay2024 #PatientSafety #WorldHealthOrganization #OtsukaCares

Meet Rachael and Maria. Two strangers bonded by their experience of becoming sandwich generation caregivers at similar phases of life, as they cared for both their parents diagnosed with frontotemporal dementia (FTD) while also navigating raising their own children. Rachael and Maria learned early on the importance of community, whether it be in-person or on social media, and found that navigating their caregiving journey became a bit simpler when they had each other to lean on, talk through the progression, and the emotions that come with it. Otsuka knows that within the mind of every caregiver, there is immeasurable love and unimaginable strength. To bring light to their unwavering dedication, Otsuka is dedicated to sharing their stories—to valuing the minds of caregivers everywhere. Watch all episodes in our Caregiver Corner playlist on our YouTube Channel: https://lnkd.in/gvbiPCzj The featured caregivers are paid collaborators of Otsuka America Pharmaceutical, Inc. #sandwichcaregiver #sandwichgeneration #caregivingstory #still here

In support of Women's Equality day, we're recognizing the work being done by the Healthcare Businesswomen’s Association (HBA) affinity group, Women in Healthcare Give Back, to advance health equity in Women's Health. Women's Equality Day commemorates the struggles of women to be heard, as fierce advocates who gained the statutory right to vote. And continues to be a day to recognize all that women have achieved and are achieving. Join us in watching the webinar hosted by Greselda Butler, CHCP, FACEHP, Director of Independent Medical Education and External Affairs, and Kathryn Godburn Schubert, Society for Women's Health Research (SWHR) as they discuss the topics of research, policy and leadership in women's health equity to enact necessary change. Watch now: https://bit.ly/3YFqsE6 #womensequalitydayeveryday

There are 12.4M people worldwide who are affected by the most common type of polycystic kidney disease (PKD) called Autosomal Dominant (ADPKD). Autosomal Recessive is a rarer form that occurs in 1 in 25,000 children worldwide. Neither of these chronic kidney diseases can be cured.     Otsuka’s perseverance in developing treatments for people living with kidney disease has led to breakthroughs that have helped change the landscape of treatment options and set the stage for other new developments in nephrology.     In addition to drug development, we have spent years advocating on behalf of patients through programs and institutions focused on kidney disease. We will continue to serve our patients and clinicians each and every day, so they can achieve more than they thought was possible.     Help spread awareness about PKD by learning more here: https://bit.ly/3QOhmAY